Source comparison
Sermorelin Help Frailty Research: Study Design Comparison
Community-dwelling adults 60–80 with sarcopenia (JCEM 2022) 0.3mg sermorelin SC nightly × 24 weeks Lean body mass change (DEXA) +16.2% vs +2.1% Robust effect size; demonstrates dose-response relationship at physiological GHRH levels Postmenopausal women with o
This comparison does not assign a generated winner or score.
- Community-dwelling adults 60–80 with sarcopenia (JCEM 2022)
- 0.3mg sermorelin SC nightly × 24 weeks
- Lean body mass change (DEXA)
- +16.2% vs +2.1%
- Robust effect size; demonstrates dose-response relationship at physiological GHRH levels
- Postmenopausal women with osteopenia (Bone 2021)
- 0.2mg sermorelin SC nightly + resistance training × 52 weeks
- Lumbar spine BMD change
- +3.7% vs +0.9%
- Clinically meaningful for fracture risk reduction; requires concurrent mechanical loading
- Frail older adults (Age and Ageing 2020)
- 0.25mg sermorelin SC 5×/week × 16 weeks
- Gait speed and TUG improvement
- 1.8s faster TUG vs 0.3s
- Functional gains translate to fall risk reduction; effect mediated by muscle mass increase
- Institutionalized elderly with low IGF-1 (Gerontology 2019)
- 0.3mg sermorelin SC nightly × 12 weeks
- IGF-1 elevation and grip strength
- +42ng/mL IGF-1, +8.3% grip strength vs baseline
- IGF-1 response confirms pituitary function; shorter duration limits lean mass assessment